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The structural properties of a selected segment of the 4 polypeptide chains of the acetylchohne receptor 
from Torpedo californica have been compared by model building studies. The particular segment (restdues 
135-142) is identical for the 8, y and 6 subunits but differs in one position from the otherwise identical 
a-peptide. We conclude that the exchange of a tryptophanyl by a glutaminyl residue may produce a sufti- 
ciently different folding and charge pattern to provide for the specific binding of cholinergic ligands to the 
cc-peptide. 
Nicotinic acetylcholine receptor Ligand binding a-Cobratosm Peptide sequence 
1. INTRODUCTION 
Based on the available amino acid sequences of 
nicotinic acetylcholine receptors [l-6], several 
structural models for this integral membrane pro- 
tein have been developed [3-5,7-lo]. These focus 
almost exclusively on the prediction of transmem- 
brane cY-helices and on the topological arrange- 
ment of these within the overall structure of the 
receptor. In contrast, the large extracellular por- 
tions of the receptor’s polypeptides are believed to 
contain mainlyfl-structural elements and, thus, are 
much less accessible to prediction [l 11. As a fur- 
ther limitation, the disulphide bridges of these 
areas have not yet been unequivocally assigned to 
particular cysteines. Accordingly, the existing 
structural predictions for the location of the ligand 
binding sites on the receptor have of necessity been 
rather vague [1,7,10,12]. 
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Prompted by the detailed knowledge available 
on the interaction with specific ligands, we have 
adopted a new approach to pinpoint regions of the 
receptor possibly involved in ligand binding: In- 
itially, we searched for the longest stretch of amino 
acids in the extracellular portions of the receptor’s 
polypeptides identical in the 3 larger subunits but 
differing from the a-subunit. Secondly, we 
employed secondary structure prediction methods 
to identify the structural elements likely to govern 
these selected sequence segments. Finally, if dif- 
ferent structural predictions were obtained for the 
a-peptide as compared to the ,8,y and b-peptides, 
detailed model building studies involving several 
representative cholinergic ligands were initiated. 
These studies showed that the exchange of a tryp- 
tophanyl (i3,y,&peptides) by a glutaminyl residue 
(ar-peptide) in an otherwise identical octapeptide 
(residues 135-142) can suffice to provide the (Y- 
subunit with the structural properties required for 
the specific binding of cholinergic ligands. 
2. METHODS 
2.1. Secondary structure prediction 
Predictions of the secondary structure of the 
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peptides 129- 147 of the LY and he P,y,G-subunits of 
the AChR were carried out according to the 
algorithms of [ 13- 161 using computer programs 
written by authors in [17] for a DEC 10 
computer. 
2.2. Model building 
Model building was done using the FRODO 
software [18] run on an Evans & Sutherland 
PS 300 Graphics System connected to a VAX 
11/750 computer. The peptide conformations were 
constructed according to the results of secondary 
structure predictions with their geometry being 
refined by applying the method of [ 191. Model 
building and refinement for the peptide CTX com- 
plex was performed by the same methods, keeping 
the coordinates for CTX as determined by X-ray 
crystallography [20]. 
3. RESULTS AND DISCUSSION 
The maximal stretch of amino acids completely 
identical in the extracellular portions of the ,~3,y 
and B-subunits but differing from the a-subunit, is 
the nonapeptide Tyr-Phe-Pro-Phe-Asp-Trp-Gln- 
Asn-Cys (residues 134-142). The related a-peptide 
has the sequence His-Phe-Pro-Phe-Asp-Gln-Gln- 
Asn-Cys. The latter is conserved in all receptor 
species sequenced so far [5,6]. 
As shown by X-ray crystallographic analysis of 
another protein [21], the exchange of a single 
amino acid in an otherwise completely 
homologous primary structure is sufficient to pro- 
duce an entirely different folding of the respective 
peptide chain. The same seems to apply for the ex- 
change of Gln for Trp in the above two nonapep- 
tide sequences. As shown in fig.1, the algorithm 
developed by authors in [13] predicts a /?-turn for 
the segment Phe-Asp-Gln-Gln of the a-peptide 
whereas this turn is shifted by one amino acid to 
the segment Pro-Phe-Asp-Trp in the ,d,y,& 
peptides. Alternative prediction methods [14-161, 
while failing to exactly reproduce the &turns 
outlined above, all predict P-turns in this region. 
Moreover, the average of these predictions closely 
matched the result obtained with the algorithm of 
[13] (fig.1). 
At first view both the cu-peptide and the P,y,& 
peptides seem to meet the requirements for an ACh 
binding site: (i) Since both appear to form P-turns 
Rd 13 
fief 14 -16 
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13‘ 
Fig.1. Secondary structure prediction [13] for the 
peptides 129-147 of the a-subunit (upper top trace) and 
the &subunit (upper lower trace) from T. californica. 
The resulting average of the 4 different predictive 
methods mentioned in the text [ 13-161 (i.e., top lower 
and bottom lower traces) is also presented. m, ,8- 
strand; Is;’ , P-turn; -, random coil. 
and also contain an N-glycosylation site (Asn-141), 
they probably reside at the surface of the receptor. 
(ii) They both contain a negatively charged residue 
(Asp-138) required as an acceptor site for the 
quaternary nitrogen moiety of ACh. (iii) They 
both contain a cysteine (Cys-142) which is known 
to exist in close vicinity of the ACh binding site: In 
the presence of cholinergic ligands a particular 
disulfide bridge on the a-subunit of the receptor is 
protected against reduction [22-241. After reduc- 
tion in the absence of protecting ligands, it is 
specifically affinity alkylated by the agonist BAC 
and the blocking agent MBTA [23,24]. 
However, if the two peptides are inspected more 
closely by model building (fig.2,3), it is readily 
seen that only the cu-peptide xhibits the structural 
properties of an ACh binding site: (i) Only in this 
peptide are Asp-138 and Cys-142 positioned on the 
same side of the p-structure (fig.2a), thereby pro- 
viding the proposed distance of = 10 A between the 
alkylation site and a centre of negative charge [22]. 
In contrast, in the predicted structure for theP,y,& 
peptides (fig.2b) this distance exceeds this limiting 
value. (ii) The only N-glycosylation site in the en- 
tire a-subunit (Asn-141) [l] is positioned ‘out of 
the way’ of the presumed ACh binding site, 
thereby allowing free access of the ligand to this 
region. Such a distinction does not exist for the 
P,y,S-peptides. In addition and although posi- 
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Asp-13s 
Fig.2. (a) Predicted conformation of the putative 
acetylcholine binding site on the cY-subunit (solid lines 
Pro-136 to Cys-142). Open lines represent the ACh 
moiety covalentty attached at Cys-142 as a result of 
affinity alkylation by BAC of DTT-treated tissue (see 
text). Note the ionic interaction between the onium 
group of the ligand and the carboxylate of Asp-138 of 
the peptide sequence. (b) Predicted conformation of the 
peptide sequence Pro-136 to Cys-142 in the P,y and 6- 
subunits of the AChR. Since the side-chains of Cys-142 
and Asp-138 orient to different sides of the &strand, 
affinity alkylation with BAC (or MBTA) as shown in the 
m-subunit is not possible. --+ Indicates the direction of 
the polypeptide chain. 
tioned ‘out of the way’, different levels of gly- 
cosylation of the cu-peptide Asn-141 could never- 
theless result in differential binding properties at 
this site [25]. (iii) The predicted structure for the cr- 
peptide provides an excellent fit to the known 
structure of the central, long loop of CTX (fig.3). 
The residues of CTX shown to specifically interact 
with the cY-peptide in the proposed model (fig.3) 
Fig.3. Suggested binding of the a-subunit peptide 
(utilising residues 136-142; solid lines) to CTX (open 
lines). For CTX the backbone of residues 19-50 is 
shown. These residues make up the central long Loop 
that is believed to bind to the AChR [ZO]. Only those 
toxin side-chains interacting with the receptor in our 
model are shown. For clarity the large lettering 
corresponds to amino acids belonging to CTX and the 
small to amino acids of the cv-peptide sequence. The 
amino acid side-chains of CTX involved in binding to 
the cu-subunit are kept in the same conformation as 
found in the crystal structure [20] with the exception of 
Lys-49 which is ‘flipped over’ [35]. The proposed 
interactions between the cu-peptide and CTX are 
(numbering corresponds to notation in the figure): (i) 
Stack between peptide Phe-137 and CTX TRP-25; (ii) 
ionic interactions between peptide Asp-138 and CTX 
LYS-23 and CTX LYS-49 (m m); (iii) H-bonding 
between peptide Gln-139 and CTX THR-47 (- - ); (iv) 
dipole enhanced H-bonding between Gin-140 of the 
peptide and ASP-38 and LYS-23 of CTX (ow). All the 
toxin residues utiiised here in binding to the a-subunit 
sequence are highly conserved in a large series of snake 
toxin sequences [36]. ---+ Indicates the direction of the 
polypeptide chain. 
have been suggested by chemical modification 
studies [26,27] to form essential components of the 
multipoint attachment pattern between receptor 
and toxin. Comparable fits with the predicted 
structure of the ,B,y.S-peptides were not possible. 
The above outlined differences in the predicted 
structures of the a-peptide as compared to the 
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@,y,G-peptides provide the basic rationale for a 
functional distinction between two closely 
homologous but not identical sequence segments 
of the receptor’s polypeptides. Assuming that the 
cr-peptide indeed contains the structural elements 
of the ACh binding site, several more observations 
can be accommodated: (i) While the ,&,y,G-peptides 
do not exhibit the established properties of an 
acetylcholine binding site, they remain closely 
homologous to this site and also may provide low 
affinity sites for cholinergic ligands [28] and be in- 
volved in recognition of different receptor ligands. 
Since the replacement of Gln by Trp in position 
139 makes this region more hydrophobic, the more 
hydrophobic class of receptor ligands, i.e., the 
local anaesthetics come into mind. Assuming the 
,&,y and d-peptides form a circular arrangement at 
the mouth of the receptor channel that is biased to 
the reception of local anaesthetics, the combina- 
tion of local anaesthetic sites v,y,S-peptides) and 
ACh sites (cr-peptides) could form an allosteric net- 
work of sites with overlapping specificities. This 
agrees with the established pharmacology of these 
classes of receptor ligands [29], the variation in 
subunit labeling patterns with irreversible non- 
competitive blockers [30,31], and the complex 
competition patterns of receptor ligands observed 
with monoclonal antibodies to the AChR [32]. (ii) 
The stretch of closely homologous amino acids in 
the 4 polypeptides of the receptor suggests a com- 
mon ancestry with functional specialisation during 
evolution. From this viewpoint it is intriguing to 
note the existence in Aplysia of a ‘nicotinic type’ 
receptor that is depolarised by procaine (a 
hydrophilic local anaesthetic) in a manner almost 
indistinguishable from ACh [33]. Furthermore, a 
recent study on Locust nicotinic receptors suggests 
that these consist of only a single type of polypep- 
tide chain [34]. Finally, it should be noted that the 
genetic codes for Trp and Gln differ in the first two 
base positions, thereby conferring considerable 
evolutionary stability. 
The proposed location of the ACh binding site 
can be tested by several biochemical methods. In 
addition to chemical modification and site- 
direction mutagenesis, enzymatic modification 
(e.g., glutaminase) and antigenic site analysis [32] 
appear particularly suited for this purpose. 
Note added in proof: While this manuscript was 
being reviewed, some direct experimental evidence 
for an MBTA binding site at the proposed position 
of Cys-142 was published [37]. 
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